The table above records the past week's changes to the progress of selected potential new products through the clinical trial...
Pipeline Watch: Phase III Readouts For Cabotegravir, Filgotinib
Listen to this article
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Keep up with the top pharma business news of the week. On the go.
More from Pipeline Watch
• By
Screaming is a powerful human behavior with deep evolutionary roots. Turning up the volume affects our bodies and brains in surprising ways, influencing stress, communication, and even group dynamics. Understanding the science behind screaming reveals its complex role in both health and society.
We may then state the above equation in this way: The work done by the resultant force acting on a particle is equal to the change in the kinetic energy of the particle.
• By
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
More from R&D
• By
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.